Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Jiangsu Simcere Pharmaceutical presents new SERDs

Nov. 10, 2021

Prelude Therapeutics presents new Mcl-1 inhibitors

Nov. 9, 2021

MDM2 and MDMX have a p53-independent role in cell-cycle progression in the absence of wild-type p53

Nov. 9, 2021

Studies of KL-11743 detail potential oncolytic activity of glucose transporter inhibitors

Nov. 8, 2021

Aryl hydrocarbon receptor modulators discovered at Dong-A ST

Nov. 8, 2021

New GTPase KRAS mutant inhibitors discovered at Incyte

Nov. 8, 2021

Discovery of HB-007, a small-molecule degrader of SUMO1

Nov. 5, 2021

Teijin Pharma and Amgen synthesize TRPC6 antagonists

Nov. 5, 2021

Qilu Pharmaceutical presents EGFR inhibitors for lung cancer

Nov. 5, 2021

Beijing Scitech-Mq Pharmaceuticals divulges EGFR and/or HER2 inhibitors

Nov. 5, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.